People | June 01, 2026
Ardena appoints Ariane de Ganck as Chief Scientific Officer
Ariane brings a strong track record within Ardena, including her leadership of the company’s drug product division since 2022
Ariane brings a strong track record within Ardena, including her leadership of the company’s drug product division since 2022
Dr. Bandichhor brings nearly two decades of experience from Dr. Reddy's Laboratories
More than five drug candidates from his team progressed to human trials including drugs like Rilematovir (Phase IIb), and Bedaquiline
Roger Dansey to become Interim Chief Oncology Officer and Johanna Bendell to join Pfizer as Oncology Chief Development Officer
Dr. Roopal Thakkar joined Abbott/AbbVie in 2003 as part of the Physician Development Program
Dr. Fesharaki most recently served as the Chief Scientific Officer and Global Head of R&D for Hikma Pharmaceuticals.
Dr. Bunker will focus on leading Research and Development (R&D) in San Diego, advancing the preclinical pipeline and optimizing the Company’s Integrated Discovery Engine.
Ganguly will execute company's strategic focus on leveraging CustomGlycan to develop novel therapeutics
Dr. Bibikova is an international leader with over 25 years of experience in genomics industry
The company plans an aggressive partnering push, with 62 pre-scheduled meetings over four days, focused on out-licensing, co-development, and strategic collaborations with global pharmaceutical and biotech players
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
